Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 402 articles:
HTML format

Single Articles

    August 2021
  1. GIATROMANOLAKI A, Anestopoulos I, Panayiotidis MI, Mitrakas A, et al
    Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:3989-3995.
    PubMed     Abstract available

  2. LAFAUY P, Silapech A, Aksorn N, Sritularak B, et al
    Millettocalyxin B Inhibits Migratory Behavior of Lung Cancer Cells via Integrin alpha5 Suppression.
    Anticancer Res. 2021;41:3843-3849.
    PubMed     Abstract available

  3. OTSUKA T, Ueda K, Furukawa T, Koriyama C, et al
    Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma.
    Anticancer Res. 2021;41:3997-4004.
    PubMed     Abstract available

  4. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available

    July 2021
  5. SHIONOYA Y, Hirohashi Y, Takahashi H, Hashimoto M, et al
    Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Anticancer Res. 2021;41:3699-3706.
    PubMed     Abstract available

  6. ZAITSU J, Yamashita Y, Ishikawa A, Saito A, et al
    Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.
    Anticancer Res. 2021;41:3673-3682.
    PubMed     Abstract available

  7. JANG SK, Hong SE, Lee DH, Kim JY, et al
    Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer Res. 2021;41:3481-3487.
    PubMed     Abstract available

    June 2021
  8. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed     Abstract available

  9. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed     Abstract available

  10. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed     Abstract available

  11. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed     Abstract available

  12. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed     Abstract available

    May 2021
  13. MASUDA T, Wakabayashi YU, Nakashima T, Nishimura Y, et al
    Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
    Anticancer Res. 2021;41:2661-2667.
    PubMed     Abstract available

  14. OKIMOTO T, Tsubata Y, Tanino R, Nakao M, et al
    ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
    Anticancer Res. 2021;41:2653-2660.
    PubMed     Abstract available

  15. SUGIURA H, Miki Y, Iwabuchi E, Saito R, et al
    Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Anticancer Res. 2021;41:2371-2381.
    PubMed     Abstract available

  16. KREJCI D, Opalka P, Krejci J, Zemanova M, et al
    Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
    Anticancer Res. 2021;41:2597-2603.
    PubMed     Abstract available

  17. AOKI K, Nagatani Y, Noma K, Tsugawa T, et al
    Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.
    Anticancer Res. 2021;41:2575-2581.
    PubMed     Abstract available

  18. HISAKANE K, Seike M, Sugano T, Matsuda K, et al
    PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2021;41:2501-2509.
    PubMed     Abstract available

  19. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available

  20. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
    Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
    Anticancer Res. 2021;41:2217-2225.
    PubMed     Abstract available

    April 2021
  21. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed     Abstract available

  22. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed     Abstract available

  23. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed     Abstract available

  24. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed     Abstract available

  25. SVATON M, Blazek J, Krakorova G, Pesek M, et al
    Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Anticancer Res. 2021;41:2053-2058.
    PubMed     Abstract available

  26. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available

    March 2021
  27. IWASHITA K, Mizuno T, Kumazawa S, Imaizumi K, et al
    Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Anticancer Res. 2021;41:1707-1711.
    PubMed     Abstract available

  28. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports.
    Anticancer Res. 2021;41:1693-1699.
    PubMed     Abstract available

  29. HIRASHIMA T, Noda Y, Suzuki H, Nasu S, et al
    Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients.
    Anticancer Res. 2021;41:1655-1662.
    PubMed     Abstract available

  30. SATO Y, Iihara H, Kinomura M, Hirose C, et al
    Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
    Anticancer Res. 2021;41:1615-1620.
    PubMed     Abstract available

  31. DIMAKAKOS E, Livanios K, Vathiotis I, Gomatou G, et al
    Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2021;41:1523-1528.
    PubMed     Abstract available

  32. ITO N, Masuda T, Nakashima T, Nakao S, et al
    Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.
    Anticancer Res. 2021;41:1497-1506.
    PubMed     Abstract available

  33. CHEN WT, Chen CH, Su HT, Yueh PF, et al
    Amentoflavone Induces Cell-cycle Arrest, Apoptosis, and Invasion Inhibition in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2021;41:1357-1364.
    PubMed     Abstract available

  34. LEE HK, Noh MH, Hong SW, Kim SM, et al
    Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems.
    Anticancer Res. 2021;41:1261-1269.
    PubMed     Abstract available

  35. GRIESING S, Liao BC, Yang JC
    CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1231-1242.
    PubMed     Abstract available

  36. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  37. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed     Abstract available

  38. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available

    February 2021
  39. AKAMATSU H, Ozawa Y, Oyanagi J, Fujimoto D, et al
    Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
    Anticancer Res. 2021;41:911-917.
    PubMed     Abstract available

  40. CLEVERS MR, Kastelijn EA, Peters BJM, Kelder H, et al
    Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:869-876.
    PubMed     Abstract available

  41. WEE CW, Kim JH, Kim HJ, Kang HC, et al
    Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.
    Anticancer Res. 2021;41:757-764.
    PubMed     Abstract available

  42. YAMAMOTO J, Aoki Y, Han Q, Sugisawa N, et al
    Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells.
    Anticancer Res. 2021;41:641-643.
    PubMed     Abstract available

  43. YAMASHITA N, Oyama T, So T, Miyata T, et al
    Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma.
    Anticancer Res. 2021;41:905-910.
    PubMed     Abstract available

  44. OSHIRO H, Tome Y, Miyake K, Higuchi T, et al
    A Novel Orthotopic Mouse Model of Lung Metastasis Using Fluorescent Patient-derived Osteosarcoma Cells.
    Anticancer Res. 2021;41:635-640.
    PubMed     Abstract available

    January 2021
  45. NIEDER C, Imingen KS, Mannsaker B, Yobuta R, et al
    Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
    Anticancer Res. 2021;41:355-358.
    PubMed     Abstract available

  46. LIU YC, Huang BH, Chung JG, Liu WL, et al
    Lenvatinib Inhibits AKT/NF-kappaB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:123-130.
    PubMed     Abstract available

  47. KAWABATA S, Connis N, Gills JJ, Hann CL, et al
    Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Anticancer Res. 2021;41:91-99.
    PubMed     Abstract available

    December 2020
  48. ASHI N, Kataoka Y, Takemura T, Shirakawa C, et al
    Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study.
    Anticancer Res. 2020;40:7141-7145.
    PubMed     Abstract available

  49. LIU B, Shiraga S, Mortenson MM, Lai J, et al
    Small Cell Lung Carcinoma and Synchronous Rectal Adenocarcinoma and Jejunal Gastrointestinal Stromal Tumor Present in a Patient With History of Laryngeal Squamous Cell Carcinoma.
    Anticancer Res. 2020;40:7053-7056.
    PubMed     Abstract available

  50. VODICKA J, Fichtl J, Sebek J, ProchAzkovA K, et al
    Outcomes and Prognostic Factors Following Surgical Treatment of Pulmonary Metastases from Colorectal Carcinoma.
    Anticancer Res. 2020;40:7045-7051.
    PubMed     Abstract available

  51. HIRASHIMA T, Kanai T, Suzuki H, Yoshida H, et al
    Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:6971-6978.
    PubMed     Abstract available

  52. MORIMOTO M, Nishino K, Wada K, Imamura F, et al
    Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Alphafter Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:6957-6970.
    PubMed     Abstract available

  53. YOON JH, Cho SG
    ADGRF4 Regulates Non-small Cell Lung Cancer Cell Invasiveness.
    Anticancer Res. 2020;40:6835-6844.
    PubMed     Abstract available

  54. WATANABE T, Sawabata N, Kawaguchi T, Yoshikawa D, et al
    Clustered Circulating Tumor Cells in Lung Adenocarcinoma: Implications of Test Results of Continuous Variables.
    Anticancer Res. 2020;40:7089-7094.
    PubMed     Abstract available

    November 2020
  55. NAGASHIMA T, Oshima T, Hiroshima Y, Yokose T, et al
    Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:6407-6416.
    PubMed     Abstract available

  56. SJOGREN K, Jacobsen KA, GrOnberg BH, Halvorsen TO, et al
    Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
    Anticancer Res. 2020;40:6399-6406.
    PubMed     Abstract available

  57. LEE SY, Slagle-Webb B, Sharma AK, Connor JR, et al
    Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment.
    Anticancer Res. 2020;40:6039-6049.
    PubMed     Abstract available

  58. HORIGUCHI H, Tsujimoto H, Shinomiya N, Matsumoto Y, et al
    A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation.
    Anticancer Res. 2020;40:6171-6178.
    PubMed     Abstract available

    October 2020
  59. CHEN HJ, Tu CY, Hsia TC, Fang HY, et al
    Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
    Anticancer Res. 2020;40:5895-5899.
    PubMed     Abstract available

  60. BASSO SMM, Del Conte A, Zuccon U, Sulfaro SC, et al
    Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion.
    Anticancer Res. 2020;40:5877-5881.
    PubMed     Abstract available

  61. YAMADA Y, Tamura T, Yamamoto Y, Ichimura H, et al
    Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
    Anticancer Res. 2020;40:5757-5764.
    PubMed     Abstract available

  62. BALBINOTTI H, Cadore NA, Dutra CS, DA Silva ED, et al
    Protein Profiling of Extracellular Vesicles Associated With Cisplatin Resistance in Lung Cancer.
    Anticancer Res. 2020;40:5509-5516.
    PubMed     Abstract available

  63. HAAG A, Jayakrishnan T, Shah D, Sandhu A, et al
    First Reported Case of Localized Extra-pulmonary Small Cell Carcinoma (EPSC) of the Esophagus Treated With Triple Therapy.
    Anticancer Res. 2020;40:5919-5923.
    PubMed     Abstract available

  64. SIMONI N, Micera R, Rossi G, Giri MG, et al
    Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
    Anticancer Res. 2020;40:5901-5907.
    PubMed     Abstract available

  65. MANOHARAN A, Lugo-Baruqui A, Ciancio G
    Radical Nephrectomy and Pulmonary Lobectomy for Renal Cell Carcinoma With Tumor Thrombus Extension into the Inferior Vena Cava and Pulmonary Arteries.
    Anticancer Res. 2020;40:5837-5844.
    PubMed     Abstract available

  66. KITAHARA H, Okamoto T, Shimamatsu S, Kohno M, et al
    LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma.
    Anticancer Res. 2020;40:5659-5666.
    PubMed     Abstract available

  67. SONODA T, Yanagitani N, Suga K, Yoshizawa T, et al
    A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.
    Anticancer Res. 2020;40:5577-5582.
    PubMed     Abstract available

  68. GERGEN AK, Kohtz PD, Halpern AL, Li A, et al
    Activation of Toll-Like Receptor 2 Promotes Proliferation of Human Lung Adenocarcinoma Cells.
    Anticancer Res. 2020;40:5361-5369.
    PubMed     Abstract available

    September 2020
  69. KOBAYASHI K, Kaira K, Kagamu H
    Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.
    Anticancer Res. 2020;40:5309-5311.
    PubMed     Abstract available

  70. NONPANYA N, Prakhongcheep O, Petsri K, Jitjaicham C, et al
    Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells.
    Anticancer Res. 2020;40:4989-4999.
    PubMed     Abstract available

  71. CHEN HL, Gong JY, Lin SC, Li S, et al
    Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies.
    Anticancer Res. 2020;40:4947-4960.
    PubMed     Abstract available

  72. FLESCHUTZ K, Walter L, Leistner R, Heinzerling L, et al
    ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4937-4946.
    PubMed     Abstract available

  73. HALLEY A, Leonetti A, Gregori A, Tiseo M, et al
    The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer.
    Anticancer Res. 2020;40:4807-4818.
    PubMed     Abstract available

  74. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed     Abstract available

    August 2020
  75. NAKAO T, Okuda T, Yoshioka H, Fujita M, et al
    Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4801-4804.
    PubMed     Abstract available

  76. TAKAHASHI Y, Soh J, Shien K, Yamamoto H, et al
    Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients.
    Anticancer Res. 2020;40:4419-4423.
    PubMed     Abstract available

  77. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer.
    Anticancer Res. 2020;40:4327-4330.
    PubMed     Abstract available

  78. TAKEUCHI A, Oguri T, Fukuda S, Sone K, et al
    Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4245-4251.
    PubMed     Abstract available

  79. TAMIYA A, Tamiya M, Go H, Inoue T, et al
    A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4229-4236.
    PubMed     Abstract available

  80. CZAJKA M, Zajkowska A, Gawlak M, Bujalska-Zadrozny M, et al
    Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung.
    Anticancer Res. 2020;40:4425-4444.
    PubMed     Abstract available

  81. CAO C, Kong MX, Kapali M, Moezardalan K, et al
    EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
    Anticancer Res. 2020;40:4401-4404.
    PubMed     Abstract available

    July 2020
  82. HOHNECK A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, et al
    Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm.
    Anticancer Res. 2020;40:4137-4145.
    PubMed     Abstract available

  83. UEDA Y, Suzuki O, Ohira S, Yagi M, et al
    The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.
    Anticancer Res. 2020;40:4095-4104.
    PubMed     Abstract available

  84. TOMITA M, Maeda R, Ayabe T, Nakamura K, et al
    Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4023-4027.
    PubMed     Abstract available

  85. NODA Y, Suzuki H, Kanai T, Samejima Y, et al
    The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.
    Anticancer Res. 2020;40:3931-3937.
    PubMed     Abstract available

  86. KUBO S, Kobayashi N, Somekawa K, Hirata M, et al
    Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.
    Anticancer Res. 2020;40:3889-3896.
    PubMed     Abstract available

  87. ORYWAL K, Jelski W, KozLowski MD, Mroczko B, et al
    Activity of Alcohol Dehydrogenase and Aldehyde Dehydrogenase in Lung Cancer Cells.
    Anticancer Res. 2020;40:3857-3863.
    PubMed     Abstract available

    June 2020
  88. ABE T, Kobayashi N, Aoshika T, Ryuno Y, et al
    Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy.
    Anticancer Res. 2020;40:3513-3517.
    PubMed     Abstract available

  89. BAXA J, Ludvik J, Sedlmair M, Flohr T, et al
    Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination.
    Anticancer Res. 2020;40:3459-3468.
    PubMed     Abstract available

  90. MOON SM, Kim JH, Kim SK, Kim S, et al
    Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Anticancer Res. 2020;40:3435-3444.
    PubMed     Abstract available

  91. TAKAHASHI K, Menju T, Nishikawa S, Miyata R, et al
    Tranilast Inhibits TGF-beta1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines.
    Anticancer Res. 2020;40:3287-3296.
    PubMed     Abstract available

  92. KIM B, Kim SW, Lim JY, Park SJ, et al
    NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2020;40:3239-3246.
    PubMed     Abstract available

  93. SP N, Kang DY, Kim DH, Yoo JS, et al
    Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis.
    Anticancer Res. 2020;40:3209-3220.
    PubMed     Abstract available

  94. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed     Abstract available

  95. PALUMBO B, Capozzi R, Bianconi F, Fravolini ML, et al
    Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With (18)F-FDG-PET/CT.
    Anticancer Res. 2020;40:3355-3360.
    PubMed     Abstract available

    May 2020
  96. YOSHIDA H, Kim YH, Sakamori Y, Nagai H, et al
    A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2981-2987.
    PubMed     Abstract available

  97. RADES D, Nguyen T, Khoa MT, Janssen S, et al
    Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2847-2851.
    PubMed     Abstract available

  98. KANAI T, Suzuki H, Yoshida H, Matsushita A, et al
    Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:2787-2793.
    PubMed     Abstract available

  99. MIYAUCHI S, Shien K, Takeda T, Araki K, et al
    Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Anticancer Res. 2020;40:2667-2673.
    PubMed     Abstract available

  100. SRIRATANASAK N, Nonpanya N, Wattanathana W, Chanvorachote P, et al
    Benzoxazine Dimer Analogue Targets Integrin beta3 in Lung Cancer Cells and Suppresses Anoikis Resistance and Migration.
    Anticancer Res. 2020;40:2583-2589.
    PubMed     Abstract available

  101. LEE TG, Kim SY, Kim HR, Kim H, et al
    Radiation Induces Autophagy via Histone H4 Lysine 20 Trimethylation in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2020;40:2537-2548.
    PubMed     Abstract available

  102. SHIBATA MA, Shibata E, Morimoto J, Kondo Y, et al
    Urethane-induced Mammary Carcinogenesis Susceptibility in Transgenic Mice Expressing a Dominant-negative TGF-beta Type II Receptor.
    Anticancer Res. 2020;40:2687-2694.
    PubMed     Abstract available

  103. AOKI M, Ueda K, Umehara T, Kamimura GO, et al
    Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma.
    Anticancer Res. 2020;40:2911-2916.
    PubMed     Abstract available

    April 2020
  104. TONE M, Inomata M, Awano N, Kuse N, et al
    Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Anticancer Res. 2020;40:2239-2246.
    PubMed     Abstract available

  105. SVATON M, Zemanova M, Zemanova P, Kultan J, et al
    Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2209-2217.
    PubMed     Abstract available

  106. MOUNTZIOS G, Mavropoulou X, Koliou GA, Linardou H, et al
    Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group.
    Anticancer Res. 2020;40:2095-2106.
    PubMed     Abstract available

  107. KIM DH, Sp N, Kang DY, Jo ES, et al
    Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G2/M Cell-cycle Arrest and Intrinsic Cell Death Pathway.
    Anticancer Res. 2020;40:1905-1913.
    PubMed     Abstract available

  108. YAN L, Rust BM, Picklo MJ
    Plasma Metabolomic Changes in Mice With Time-restricted Feeding-attenuated Spontaneous Metastasis of Lewis Lung Carcinoma.
    Anticancer Res. 2020;40:1833-1841.
    PubMed     Abstract available

  109. YAMAMOTO T, Niibe Y, Matsumoto Y, Dekura Y, et al
    Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors.
    Anticancer Res. 2020;40:2065-2072.
    PubMed     Abstract available

  110. TU YN, Tong WL, Callahan BM, Chobrutskiy BI, et al
    B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate.
    Anticancer Res. 2020;40:2043-2051.
    PubMed     Abstract available

  111. ZHAO S, Guo X, Taniguchi M, Kondo K, et al
    Detection of Mediastinal Lymph Node Metastases Using Indocyanine Green (ICG) Fluorescence Imaging in an Orthotopic Implantation Model.
    Anticancer Res. 2020;40:1875-1882.
    PubMed     Abstract available

  112. SHUKUYA T, Oyanagi J, Serizawa M, Watanabe M, et al
    Hypoxia Inducible Factor-1alpha Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2020;40:1867-1874.
    PubMed     Abstract available

  113. LUU TT, Bach DH, Kim D, Hu R, et al
    Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
    Anticancer Res. 2020;40:1855-1866.
    PubMed     Abstract available

  114. HOFFMANN M, Reitz D, Taugner J, Roengvoraphoj O, et al
    Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:2319-2322.
    PubMed     Abstract available

  115. SCHALLIER D, Lesfevre P, Everaert H
    Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report.
    Anticancer Res. 2020;40:2265-2269.
    PubMed     Abstract available

  116. SIMETIC L, Blazicevic K, Medugorac K, Golcic M, et al
    Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Anticancer Res. 2020;40:2157-2163.
    PubMed     Abstract available

    March 2020
  117. NAKAO M, Fujita K, Suzuki Y, Arakawa S, et al
    Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review.
    Anticancer Res. 2020;40:1579-1585.
    PubMed     Abstract available

  118. CHAI WH, Li YR, Lin SH, Chao YH, et al
    Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In Vitro and In Vivo.
    Anticancer Res. 2020;40:1405-1417.
    PubMed     Abstract available

  119. LIU Y, Huber RM, Kiefl R, Tufman A, et al
    Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells.
    Anticancer Res. 2020;40:1451-1458.
    PubMed     Abstract available

  120. DURAN-MORENO J, Kokkali S, Ramfidis V, Salomidou M, et al
    Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.
    Anticancer Res. 2020;40:1697-1703.
    PubMed     Abstract available

  121. ARSHI J, Sauer M, Yin F
    Rapid Sarcomatoid Transformation of Lung Squamous Cell Carcinoma After Neoadjuvant Therapy: A Case Report.
    Anticancer Res. 2020;40:1625-1629.
    PubMed     Abstract available

  122. IMAI H, Kaira K, Naruse I, Kasahara N, et al
    Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Anticancer Res. 2020;40:1571-1578.
    PubMed     Abstract available

  123. SAKATA KI, Maeda K, Sakurai N, Liang S, et al
    ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
    Anticancer Res. 2020;40:1307-1314.
    PubMed     Abstract available

    February 2020
  124. NAKANO T, Go T, Nakashima N, Liu D, et al
    Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:1007-1014.
    PubMed     Abstract available

  125. PEZZUTO A, Cappuzzo F, D'Arcangelo M, Ciccozzi M, et al
    Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1.
    Anticancer Res. 2020;40:983-990.
    PubMed     Abstract available

  126. NAKAMURA Y, Miyazaki K, Aiko N, Misumi Y, et al
    Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2020;40:923-928.
    PubMed     Abstract available

  127. IOANNIDIS G, Papadaki C, Lagoudaki E, Tzardi M, et al
    Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:901-913.
    PubMed     Abstract available

  128. KITA Y, Go T, Nakashima N, Liu D, et al
    Inhibition of Cell-surface Molecular GPR87 With GPR87-suppressing Adenoviral Vector Disturb Tumor Proliferation in Lung Cancer Cells.
    Anticancer Res. 2020;40:733-741.
    PubMed     Abstract available

  129. CHANVORACHOTE P, Sriratanasak N, Nonpanya N
    C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target.
    Anticancer Res. 2020;40:609-618.
    PubMed     Abstract available

  130. KASHIWABARA K, Fuji S, Tsumura S, Sakamoto K, et al
    Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study.
    Anticancer Res. 2020;40:1117-1121.
    PubMed     Abstract available

  131. NIEDER C, Dalhaug A, Pawinski A
    Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy.
    Anticancer Res. 2020;40:977-981.
    PubMed     Abstract available

  132. OKAUCHI S, Numata T, Nawa T, Ichimura H, et al
    Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study.
    Anticancer Res. 2020;40:957-964.
    PubMed     Abstract available

    January 2020
  133. GIANONCELLI L, Spitaleri G, Passaro A, Radice D, et al
    Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
    Anticancer Res. 2020;40:427-433.
    PubMed     Abstract available

  134. OKAUCHI S, Watanabe H, Yamada H, Sato S, et al
    The Prognosis of Lung Cancer With Different Metastatic Patterns.
    Anticancer Res. 2020;40:421-426.
    PubMed     Abstract available

  135. WATANABE H, Okauchi S, Yamada H, Sato S, et al
    Application of Cluster Analysis to Distant Metastases from Lung Cancer.
    Anticancer Res. 2020;40:413-419.
    PubMed     Abstract available

  136. NIIBE Y, Yamamoto T, Onishi H, Yamashita H, et al
    Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients.
    Anticancer Res. 2020;40:393-399.
    PubMed     Abstract available

  137. ANZAI M, Yamamoto N, Hayashi K, Nakajima M, et al
    Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:379-386.
    PubMed     Abstract available

  138. MIN HY, Jung Y, Park KH, Lee HY, et al
    Papuamine Inhibits Viability of Non-small Cell Lung Cancer Cells by Inducing Mitochondrial Dysfunction.
    Anticancer Res. 2020;40:323-333.
    PubMed     Abstract available

  139. KAIRA K, Shimizu K, Endoh H, Imaizumi K, et al
    Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2020;40:261-269.
    PubMed     Abstract available

    December 2019
  140. VINAYANUWATTIKUN C, Prakhongcheep O, Tungsukruthai S, Petsri K, et al
    Feasibility Technique of Low-passage In Vitro Drug Sensitivity Testing of Malignant Pleural Effusion from Advanced-stage Non-small Cell Lung Cancer for Prediction of Clinical Outcome.
    Anticancer Res. 2019;39:6981-6988.
    PubMed     Abstract available

  141. RADES D, Glatzel E, Werner EM, Bohnet S, et al
    Prevalence and Characteristics of Symptomatic Pneumonitis After Radiotherapy of Patients With Locally Advanced Lung Cancer.
    Anticancer Res. 2019;39:6909-6913.
    PubMed     Abstract available

  142. INOMATA M, Kado T, Okazawa S, Imanishi S, et al
    Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Anticancer Res. 2019;39:6887-6893.
    PubMed     Abstract available

  143. HASEGAWA T, Yanagitani N, Utsumi H, Wakui H, et al
    Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:6851-6857.
    PubMed     Abstract available

  144. ZINNAH KMA, Park SY
    Duloxetine Enhances TRAIL-mediated Apoptosis via AMPK-mediated Inhibition of Autophagy Flux in Lung Cancer Cells.
    Anticancer Res. 2019;39:6621-6633.
    PubMed     Abstract available

  145. GOSAIN R, Groman A, Yendamuri SS, Iyer R, et al
    Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis.
    Anticancer Res. 2019;39:6835-6842.
    PubMed     Abstract available

  146. YASUKAWA M, Sawabata N, Kawaguchi T, Taniguchi S, et al
    Effectiveness of Intraoperative Pulmonary Wedge Resection of Tumor Site Before Lobectomy for Early Lung Adenocarcinoma.
    Anticancer Res. 2019;39:6829-6834.
    PubMed     Abstract available

  147. JIN HO, Hong SE, Kim JY, Jang SK, et al
    Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions.
    Anticancer Res. 2019;39:6723-6730.
    PubMed     Abstract available

  148. SATO E, Ohta S, Kawakami K, Ikeda M, et al
    Tetrandrine Increases the Sensitivity of Human Lung Adenocarcinoma PC14 Cells to Gefitinib by Lysosomal Inhibition.
    Anticancer Res. 2019;39:6585-6593.
    PubMed     Abstract available

    November 2019
  149. HO ML, Kuo WK, Chu LJ, Yeh IH, et al
    N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.
    Anticancer Res. 2019;39:6317-6324.
    PubMed     Abstract available

  150. TAKAHASHI Y, Fukuyama T, Futawatari N, Ichiki Y, et al
    Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.
    Anticancer Res. 2019;39:6259-6263.
    PubMed     Abstract available

  151. KURODA A, Matsumoto S, Fukuda A, Nakamichi T, et al
    The mTOR Signaling Pathway Is Associated With the Prognosis of Malignant Pleural Mesothelioma After Multimodality Therapy.
    Anticancer Res. 2019;39:6241-6247.
    PubMed     Abstract available

  152. HIRASHIMA T, Kanai T, Suzuki H, Yoshida H, et al
    The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:6231-6240.
    PubMed     Abstract available

  153. CHO E, Than TT, Kim SH, Park ER, et al
    G3BP1 Depletion Increases Radiosensitisation by Inducing Oxidative Stress in Response to DNA Damage.
    Anticancer Res. 2019;39:6087-6095.
    PubMed     Abstract available

  154. LIU JB, Hu L, Yang Z, Sun YU, et al
    Aurora-A/NF-kB Signaling Is Associated With Radio-resistance in Human Lung Adenocarcinoma.
    Anticancer Res. 2019;39:5991-5998.
    PubMed     Abstract available

  155. LEHTOMAKI KI, Lahtinen LI, Rintanen N, Kuopio T, et al
    Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.
    Anticancer Res. 2019;39:5867-5877.
    PubMed     Abstract available

    October 2019
  156. NAKAO S, Yamaguchi K, Sakamoto S, Horimasu Y, et al
    Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
    Anticancer Res. 2019;39:5725-5731.
    PubMed     Abstract available

  157. NASU S, Okamoto N, Suzuki H, Shiroyama T, et al
    Comparison of the Utilities of Cryobiopsy and Forceps Biopsy for Peripheral Lung Cancer.
    Anticancer Res. 2019;39:5683-5688.
    PubMed     Abstract available

  158. ZHANG Q, Song Y, Cheng X, Xu Z, et al
    Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
    Anticancer Res. 2019;39:5461-5471.
    PubMed     Abstract available

  159. CHEN GL, Wang SC, Huang WC, Chang WS, et al
    The Association of MMP-11 Promoter Polymorphisms With Susceptibility to Lung Cancer in Taiwan.
    Anticancer Res. 2019;39:5375-5380.
    PubMed     Abstract available

  160. NAKANISHI K, Sakakura N, Matsui T, Ueno H, et al
    Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2019;39:5789-5795.
    PubMed     Abstract available

  161. REYNEL M, Villegas Y, Kiene H, Werthmann PG, et al
    Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion.
    Anticancer Res. 2019;39:5597-5604.
    PubMed     Abstract available

  162. ALTURKISTANI A, Ghonem N, Power-Charnitsky VA, Pino-Figueroa A, et al
    Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.
    Anticancer Res. 2019;39:5297-5310.
    PubMed     Abstract available

    September 2019
  163. GE H, Cheng N, Xu X, Yang Z, et al
    AMMECR1 Inhibits Apoptosis and Promotes Cell-cycle Progression and Proliferation of the A549 Human Lung Cancer Cell Line.
    Anticancer Res. 2019;39:4637-4642.
    PubMed     Abstract available

  164. BUENTZEL J, Heinz J, Bleckmann A, Bauer C, et al
    Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis.
    Anticancer Res. 2019;39:4603-4612.
    PubMed     Abstract available

  165. FONTANA V, Pistillo MP, Vigani A, Canessa PA, et al
    Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
    Anticancer Res. 2019;39:5219-5223.
    PubMed     Abstract available

  166. ANDO K, Hamada K, Watanabe M, Ohkuma R, et al
    Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
    Anticancer Res. 2019;39:5195-5201.
    PubMed     Abstract available

  167. KASMANN L, Taugner J, Eze C, Roengvoraphoj O, et al
    Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
    Anticancer Res. 2019;39:5077-5081.
    PubMed     Abstract available

  168. HARADA D, Takata K, Mori S, Kozuki T, et al
    Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Anticancer Res. 2019;39:4987-4993.
    PubMed     Abstract available

  169. KIYUNA T, Tome Y, Miyake K, Murakami T, et al
    Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2019;39:4775-4779.
    PubMed     Abstract available

    August 2019
  170. KOTSANTIS I, Economopoulou P, Psyrri A, Maratou E, et al
    Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:4185-4190.
    PubMed     Abstract available

  171. MORISAKI T, Kubo M, Umebayashi M, Yuan Y, et al
    Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy.
    Anticancer Res. 2019;39:4517-4523.
    PubMed     Abstract available

  172. CORTINOVIS D, Chiari R, Catino A, Grossi F, et al
    Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.
    Anticancer Res. 2019;39:4265-4271.
    PubMed     Abstract available

  173. UDA NR, Stenner F, Seibert V, Herzig P, et al
    Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.
    Anticancer Res. 2019;39:4117-4128.
    PubMed     Abstract available

  174. YOON SN, Park JH, Lwin TM, Miyake K, et al
    Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis.
    Anticancer Res. 2019;39:4065-4071.
    PubMed     Abstract available

    July 2019
  175. GIULIANI J, Bonetti A
    Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.
    Anticancer Res. 2019;39:3961-3965.
    PubMed     Abstract available

  176. FUJITA K, Uchida N, Yamamoto Y, Kanai O, et al
    Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
    Anticancer Res. 2019;39:3917-3921.
    PubMed     Abstract available

  177. DRAG-ZALESINSKA M, Saczko J, Choromanska A, Szewczyk A, et al
    Cisplatin and Vinorelbine -Mediated Electrochemotherapeutic Approach Against Multidrug Resistant Small Cell Lung Cancer (H69AR) In Vitro.
    Anticancer Res. 2019;39:3711-3718.
    PubMed     Abstract available

  178. TAMIYA M, Tamiya A, Suzuki H, Moriizumi K, et al
    Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
    Anticancer Res. 2019;39:3923-3929.
    PubMed     Abstract available

  179. GEROGIANNI I, Pitaraki E, Jagirdar RM, Kouliou O, et al
    2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Anticancer Res. 2019;39:3809-3814.
    PubMed     Abstract available

  180. RODRIGUEZ-CORDOVA RJ, Gutierrez-Valenzuela CA, Bojang P, Esquivel R, et al
    Differential Response of BEAS-2B and H-441 Cells to Methylene Blue Photoactivation.
    Anticancer Res. 2019;39:3739-3744.
    PubMed     Abstract available

    June 2019
  181. CHASZCZEWSKA-MARKOWSKA M, Kosacka M, Chryplewicz A, Dyla T, et al
    ECCR1 and NFKB2 Polymorphisms as Potential Biomarkers of Non-small Cell Lung Cancer in a Polish Population.
    Anticancer Res. 2019;39:3269-3272.
    PubMed     Abstract available

  182. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Patterns of End-of-Life Oncologic Care for Stage IV Non-small Cell Lung Cancer in the United States.
    Anticancer Res. 2019;39:3137-3140.
    PubMed     Abstract available

  183. WOUTERS A, Durieux V, Kolivras A, Meert AP, et al
    Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review.
    Anticancer Res. 2019;39:3003-3008.
    PubMed     Abstract available

  184. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Comparison Between Stereotactic and Conventional Radiotherapy for Solitary Lung Tumor After Resection of Lung Cancer.
    Anticancer Res. 2019;39:2957-2962.
    PubMed     Abstract available

  185. HU M, Tang Y, Long G, Zhang D, et al
    Primary Extracranial Meningioma of Mastoid in a Patient With History of Skin Squamous Cell Carcinoma, Lung Adenocarcinoma and Prostatic Carcinoma.
    Anticancer Res. 2019;39:3197-3201.
    PubMed     Abstract available

    May 2019
  186. KAWACHI H, Fujimoto D, Yamashita D, Fukuoka J, et al
    Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
    Anticancer Res. 2019;39:2561-2567.
    PubMed     Abstract available

  187. KAIRA K, Imai H, Souma R, Sakurai R, et al
    An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:2483-2491.
    PubMed     Abstract available

  188. ERCAN S, Arinc S, Yilmaz SG, Altunok C, et al
    Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:2437-2441.
    PubMed     Abstract available

  189. KINOSHITA F, Toyokawa G, Matsubara T, Kozuma Y, et al
    Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.
    Anticancer Res. 2019;39:2665-2670.
    PubMed     Abstract available

  190. LINDBLOM EK, Dasu A, Toma-Dasu I
    Hypoxia Induced by Vascular Damage at High Doses Could Compromise the Outcome of Radiotherapy.
    Anticancer Res. 2019;39:2337-2340.
    PubMed     Abstract available

    April 2019
  191. SHINOHARA S, Otsuki R, Onitsuka T, Machida K, et al
    Postoperative C-reactive Protein Is a Predictive Biomarker for Survival After Non-small Cell Lung Cancer Resection.
    Anticancer Res. 2019;39:2193-2198.
    PubMed     Abstract available

  192. TAKADA K, Shimokawa M, Akamine T, Ono Y, et al
    Association of Low Body Mass Index With Poor Clinical Outcomes After Resection of Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1987-1996.
    PubMed     Abstract available

  193. CHECK JH, Check D, Poretta T
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Anticancer Res. 2019;39:1923-1926.
    PubMed     Abstract available

  194. KURIHARA E, Shien K, Torigoe H, Takeda T, et al
    Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:1767-1775.
    PubMed     Abstract available

  195. YAN L, Sundaram S, Mehus AA, Picklo MJ, et al
    Time-restricted Feeding Attenuates High-fat Diet-enhanced Spontaneous Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1739-1748.
    PubMed     Abstract available

  196. SUNDARAM S, Yan L
    Adipose-specific Monocyte Chemotactic Protein-1 Deficiency Reduces Pulmonary Metastasis of Lewis Lung Carcinoma in Mice.
    Anticancer Res. 2019;39:1729-1738.
    PubMed     Abstract available

    March 2019

  197. Oxford Case Histories in Lung Cancer.
    Anticancer Res. 2019;39:1633.

  198. NAKASHIMA K, Akamatsu H, Murakami H, Niwa T, et al
    Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1463-1468.
    PubMed     Abstract available

  199. KASAHARA N, Sunaga N, Tsukagoshi Y, Miura Y, et al
    Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1.
    Anticancer Res. 2019;39:1455-1461.
    PubMed     Abstract available

  200. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Abstract available

  201. YASUKAWA M, Ohbayashi C, Kawaguchi T, Kawai N, et al
    Analysis of Histological Grade in Resected Lung-invasive Adenocarcinoma.
    Anticancer Res. 2019;39:1491-1500.
    PubMed     Abstract available

  202. CHO BC, DE Pas T, Kalofonos H, Wang Q, et al
    Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.
    Anticancer Res. 2019;39:1403-1409.
    PubMed     Abstract available

  203. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
    Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
    Anticancer Res. 2019;39:1343-1346.
    PubMed     Abstract available

  204. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Abstract available

  205. ONISHI H, Yamasaki A, Nakamura K, Ichimiya S, et al
    Liprin-alpha4 as a New Therapeutic Target for SCLC as an Upstream Mediator of HIF1alpha.
    Anticancer Res. 2019;39:1179-1184.
    PubMed     Abstract available

    February 2019
  206. SARUWATARI K, Ikeda T, Saeki S, Shingu N, et al
    Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Anticancer Res. 2019;39:923-931.
    PubMed     Abstract available

  207. PARIKH AB, Hammons L, Gomez JE
    Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review.
    Anticancer Res. 2019;39:897-902.
    PubMed     Abstract available

  208. KATSURADA M, Nagano T, Tachihara M, Kiriu T, et al
    Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:815-825.
    PubMed     Abstract available

  209. KUBO N, Harada T, Shiraishi Y, Nosaki K, et al
    Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer.
    Anticancer Res. 2019;39:671-677.
    PubMed     Abstract available

  210. AKSORN N, Chanvorachote P
    Integrin as a Molecular Target for Anti-cancer Approaches in Lung Cancer.
    Anticancer Res. 2019;39:541-548.
    PubMed     Abstract available

  211. MIYAKE H, Matsushita Y, Watanabe H, Tamura K, et al
    Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
    Anticancer Res. 2019;39:1067-1072.
    PubMed     Abstract available

  212. SALO SAS, Ilonen I, Laaksonen S, Myllarniemi M, et al
    Malignant Peritoneal Mesothelioma: Treatment Options and Survival.
    Anticancer Res. 2019;39:839-845.
    PubMed     Abstract available

  213. SUKARI A, Nagasaka M, Alhasan R, Patel D, et al
    Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Anticancer Res. 2019;39:781-790.
    PubMed     Abstract available

  214. NAKAYAMA K, Seike M, Noro R, Takeuchi S, et al
    Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
    Anticancer Res. 2019;39:627-633.
    PubMed     Abstract available

    January 2019
  215. WADA K, Kishi N, Kanayama N, Hirata T, et al
    Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy.
    Anticancer Res. 2019;39:491-497.
    PubMed     Abstract available

  216. KUO WI, Cheng KH, Chang YJ, Wu TT, et al
    Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts.
    Anticancer Res. 2019;39:183-190.
    PubMed     Abstract available

  217. KAIRA K, Kamiyoshihara M, Kawashima O, Endoh H, et al
    Prognostic Impact of beta2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2019;39:395-403.
    PubMed     Abstract available

  218. CHU CN, Wu KC, Chung WS, Zheng LC, et al
    Etomidate Suppresses Invasion and Migration of Human A549 Lung Adenocarcinoma Cells.
    Anticancer Res. 2019;39:215-223.
    PubMed     Abstract available

    December 2018
  219. FUJIMOTO D, Yamashita D, Fukuoka J, Kitamura Y, et al
    Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Anticancer Res. 2018;38:6891-6895.
    PubMed     Abstract available

  220. SVATON M, Zemanova M, Skrickova J, Jakubikova L, et al
    Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:6771-6782.
    PubMed     Abstract available

  221. TAMIYA H, Mitani A, Saito A, Ishimori T, et al
    Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion.
    Anticancer Res. 2018;38:6707-6714.
    PubMed     Abstract available

    November 2018
  222. AKAIKE K, Saruwatari K, Okabayashi H, Hamada S, et al
    Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.
    Anticancer Res. 2018;38:6543-6550.
    PubMed     Abstract available

  223. WU MF, Wang YC, Li HT, Chen WC, et al
    The Contribution of Interleukin-12 Genetic Variations to Taiwanese Lung Cancer.
    Anticancer Res. 2018;38:6321-6327.
    PubMed     Abstract available

  224. MOENG S, Seo HA, Hwang CY, Cipolla GA, et al
    MicroRNA-107 Targets IKBKG and Sensitizes A549 Cells to Parthenolide.
    Anticancer Res. 2018;38:6309-6316.
    PubMed     Abstract available

  225. LIU KH, Tsai YT, Chin SY, Lee WR, et al
    Hypoxia Stimulates the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells Through Accumulation of Nuclear beta-Catenin.
    Anticancer Res. 2018;38:6299-6308.
    PubMed     Abstract available

  226. PHIBOONCHAIYANAN PP, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells via p53 Activation and Down-regulation of Survivin.
    Anticancer Res. 2018;38:6281-6290.
    PubMed     Abstract available

    October 2018
  227. WADA K, Kishi N, Kanayama N, Hirata T, et al
    Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.
    Anticancer Res. 2018;38:5951-5958.
    PubMed     Abstract available

  228. TAKAMORI S, Takada K, Azuma K, Jogo Y, et al
    Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Anticancer Res. 2018;38:5903-5907.
    PubMed     Abstract available

  229. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Abstract available

  230. CHEN GL, Shen TC, Chang WS, Tsai CW, et al
    The Contribution of MMP-7 Promoter Polymorphisms to Taiwan Lung Cancer Susceptibility.
    Anticancer Res. 2018;38:5671-5677.
    PubMed     Abstract available

  231. YOUSSEF O, Knuuttila A, Piirila P, Bohling T, et al
    Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Anticancer Res. 2018;38:5627-5634.
    PubMed     Abstract available

  232. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Abstract available

  233. YOON N, Kim J, Maeng LS, Ahn JH, et al
    Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:6003-6008.
    PubMed     Abstract available

  234. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Abstract available

    September 2018
  235. TAKEUCHI A, Oguri T, Yamashita Y, Sone K, et al
    TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5489-5495.
    PubMed     Abstract available

  236. EZE C, Roengvoraphoj O, Dantes M, Abdo R, et al
    Prophylactic Cranial Irradiation for Patients with Small Cell Lung Cancer in Germany: Pattern of Care Survey.
    Anticancer Res. 2018;38:5261-5265.
    PubMed     Abstract available

  237. WU JY, Lin SS, Hsu FT, Chung JG, et al
    Fluoxetine Inhibits DNA Repair and NF-kB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5201-5210.
    PubMed     Abstract available

  238. HUANG YP, Jiang YW, Chen HY, Hsiao YT, et al
    Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:5165-5176.
    PubMed     Abstract available

  239. KURAMOTO K, Yamamoto M, Suzuki S, Sanomachi T, et al
    AS602801, an Anti-Cancer Stem Cell Drug Candidate, Suppresses Gap-junction Communication Between Lung Cancer Stem Cells and Astrocytes.
    Anticancer Res. 2018;38:5093-5099.
    PubMed     Abstract available

  240. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:5057-5065.
    PubMed     Abstract available

  241. HAKOZAKI M, Tamura H, Dobashi Y, Yoshida A, et al
    Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination.
    Anticancer Res. 2018;38:5035-5042.
    PubMed     Abstract available

  242. RONCHI L, Buwenge M, Cortesi A, Ammendolia I, et al
    Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma.
    Anticancer Res. 2018;38:4977-4985.
    PubMed     Abstract available

  243. MILLETT RL, Elkon JM, Tabbara IA
    Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4969-4975.
    PubMed     Abstract available

  244. MIYAZAKI K, Tamura T, Kaburagi T, Saito K, et al
    Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation.
    Anticancer Res. 2018;38:5409-5415.
    PubMed     Abstract available

  245. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Abstract available

  246. TAKADA K, Toyokawa G, Tagawa T, Shimokawa M, et al
    Radiological Features of IDO1(+)/PDL1(+) Lung Adenocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2018;38:5295-5303.
    PubMed     Abstract available

  247. FURUTA H, Uemura T, Yoshida T, Kobara M, et al
    Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment.
    Anticancer Res. 2018;38:5231-5237.
    PubMed     Abstract available

    August 2018
  248. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Abstract available

  249. SHIMIZU K, Okita R, Saisho S, Maeda AI, et al
    Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4637-4644.
    PubMed     Abstract available

  250. ONISHI H, Ichimiya S, Yanai K, Umebayashi M, et al
    RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
    Anticancer Res. 2018;38:4543-4547.
    PubMed     Abstract available

  251. LEE J, Yun HH, Kim S, Ji SH, et al
    Implication of BIS in the Migration and Invasion of A549 Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:4525-4533.
    PubMed     Abstract available

  252. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Abstract available

  253. WATANABE S, Yamaguchi OU, Masumoto AI, Maeno Y, et al
    Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
    Anticancer Res. 2018;38:4699-4704.
    PubMed     Abstract available

    July 2018
  254. BAXA J, Matouskova T, Ludvik J, Sedlmair M, et al
    Single-source Dual-energy CT as a Part of (18)F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4131-4137.
    PubMed     Abstract available

  255. SCHMID S, Csanadi A, Kozhuharov N, Tchudjin M, et al
    CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3913-3918.
    PubMed     Abstract available

  256. MAIUTHED A, Chantarawong W, Chanvorachote P
    Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
    Anticancer Res. 2018;38:3797-3809.
    PubMed     Abstract available

  257. ARIMOTO A, Yamashita K, Hasegawa H, Sugita Y, et al
    Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis.
    Anticancer Res. 2018;38:4333-4338.
    PubMed     Abstract available

  258. TUPY R, Mirka H, Mracek J, Priban V, et al
    Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4149-4152.
    PubMed     Abstract available

  259. USUDA K, Iwai S, Funasaki A, Sekimura A, et al
    Expression and Prognostic Impact of VEGF, CD31 and alphaSMA in Resected Primary Lung Cancers.
    Anticancer Res. 2018;38:4057-4063.
    PubMed     Abstract available

  260. BASSANELLI M, Sioletic S, Martini M, Giacinti S, et al
    Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Anticancer Res. 2018;38:3789-3796.
    PubMed     Abstract available

    June 2018
  261. TAKEOKA H, Yamada K, Naito Y, Matsuo N, et al
    Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Anticancer Res. 2018;38:3779-3784.
    PubMed     Abstract available

  262. SHOJI F, Yamazaki K, Miura N, Katsura M, et al
    Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3773-3778.
    PubMed     Abstract available

  263. SYRIGOS KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, et al
    Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.
    Anticancer Res. 2018;38:3735-3744.
    PubMed     Abstract available

  264. TAKAMORI S, Toyokawa G, Shimokawa M, Kinoshita F, et al
    Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Anticancer Res. 2018;38:3731-3734.
    PubMed     Abstract available

  265. TOYOKAWA G, Takada K, Tagawa T, Kinoshita F, et al
    Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:3707-3711.
    PubMed     Abstract available

  266. BANNA GL, Camerini A, Bronte G, Anile G, et al
    Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.
    Anticancer Res. 2018;38:3689-3697.
    PubMed     Abstract available

  267. MATSUMOTO T, Hasebe T, Baba Y, Chosa K, et al
    Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3587-3592.
    PubMed     Abstract available

  268. RAUNGRUT P, Wongkotsila A, Champoochana N, Lirdprapamongkol K, et al
    Knockdown of 14-3-3gamma Suppresses Epithelial-Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:3507-3514.
    PubMed     Abstract available

  269. KOYI H, Branden E, Kasim I, Wilander E, et al
    Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:3341-3346.
    PubMed     Abstract available

  270. LAI JZ, Lai HH, Cao D
    Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Anticancer Res. 2018;38:3757-3761.
    PubMed     Abstract available

  271. HAGI T, Nakamura T, Sugino Y, Matsubara T, et al
    Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma?
    Anticancer Res. 2018;38:3635-3639.
    PubMed     Abstract available

  272. MASUHIRO K, Shiroyama T, Suzuki H, Takata SO, et al
    Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring EGFR T790M.
    Anticancer Res. 2018;38:3567-3571.
    PubMed     Abstract available

  273. KOMIYA K, Nakashima C, Nakamura T, Hirakawa H, et al
    Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy.
    Anticancer Res. 2018;38:3559-3566.
    PubMed     Abstract available

  274. LIN MX, Lin SH, Lin CC, Yang CC, et al
    In Vitro and In Vivo Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:3435-3445.
    PubMed     Abstract available

  275. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Abstract available

    May 2018
  276. SHINOHARA S, Sugaya M, Onitsuka T, Machida K, et al
    Prognostic Impact of Postoperative C-reactive Protein for Non-small Cell Lung Cancer Following Lobectomy.
    Anticancer Res. 2018;38:3193-3198.
    PubMed     Abstract available

  277. KINOSHITA F, Toyokawa G, Tagawa T, Matsubara T, et al
    Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.
    Anticancer Res. 2018;38:2957-2960.
    PubMed     Abstract available

  278. ALMQUIST D, Khanal N, Smith L, Ganti AK, et al
    Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
    Anticancer Res. 2018;38:2903-2907.
    PubMed     Abstract available

  279. LIAO TY, Liaw CC, Tsui KH, Juan YH, et al
    Renal Pelvis Carcinoma with Renal Vein or Inferior Vena Cava Involvement Linked to Early-onset Lung Metastasis Based on CT Scan Diagnosis.
    Anticancer Res. 2018;38:3187-3192.
    PubMed     Abstract available

  280. KABURAGI T, Kiyoshima M, Nawa T, Ichimura H, et al
    Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
    Anticancer Res. 2018;38:3145-3150.
    PubMed     Abstract available

  281. KAWAGUCHI Y, Okano T, Kakihana M, Kajiwara N, et al
    Transition Rate from EGFR-TKI to Cytotoxic Chemotherapy Patients with EGFR Mutation-positive Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3127-3132.
    PubMed     Abstract available

  282. TANAKA K, Toyokawa G, Tagawa T, Ijichi K, et al
    Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.
    Anticancer Res. 2018;38:3115-3118.
    PubMed     Abstract available

  283. OHNO T, Kubouchi Y, Wakahara M, Nosaka K, et al
    Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma.
    Anticancer Res. 2018;38:3001-3007.
    PubMed     Abstract available

    April 2018
  284. TAKEMURA Y, Chihara Y, Morimoto Y, Tanimura K, et al
    Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2385-2390.
    PubMed     Abstract available

  285. LUND-IVERSEN M, Scott H, Strom EH, Theiss N, et al
    Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2261-2269.
    PubMed     Abstract available

  286. VO VTA, Choi JW, Phan ANH, Hua TNM, et al
    TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:2187-2193.
    PubMed     Abstract available

  287. CHEN WT, Chen YK, Lin SS, Hsu FT, et al
    Hyperforin Suppresses Tumor Growth and NF-kappaB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2161-2167.
    PubMed     Abstract available

  288. BIANCONI F, Fravolini ML, Bello-Cerezo R, Minestrini M, et al
    Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:2155-2160.
    PubMed     Abstract available

  289. HSIA TC, Huang YP, Jiang YW, Chen HY, et al
    Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro.
    Anticancer Res. 2018;38:2137-2147.
    PubMed     Abstract available

  290. KANAJI N, Yokohira M, Watanabe N, Kadowaki N, et al
    Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype.
    Anticancer Res. 2018;38:2007-2014.
    PubMed     Abstract available

  291. MATSUMOTO N, Kumasaka A, Ando T, Komiyama K, et al
    Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method.
    Anticancer Res. 2018;38:2093-2099.
    PubMed     Abstract available

  292. RZECHONEK A, Grzegrzolka J, Blasiak P, Ornat M, et al
    Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers.
    Anticancer Res. 2018;38:1987-1991.
    PubMed     Abstract available

  293. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Abstract available

    March 2018
  294. TOYOKAWA G, Yamada Y, Tagawa T, Kinoshita F, et al
    High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:1821-1825.
    PubMed     Abstract available

  295. NASU S, Suzuki H, Shiroyama T, Tanaka A, et al
    Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
    Anticancer Res. 2018;38:1783-1788.
    PubMed     Abstract available

  296. MATSUBARA T, Toyokawa G, Kinoshita F, Haratake N, et al
    Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors.
    Anticancer Res. 2018;38:1715-1719.
    PubMed     Abstract available

  297. SATO Y, Fujimoto D, Uehara K, Kawachi H, et al
    Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
    Anticancer Res. 2018;38:1401-1405.
    PubMed     Abstract available

    February 2018
  298. KATO Y, Kashima J, Watanabe K, Yomota M, et al
    Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:1077-1083.
    PubMed     Abstract available

  299. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Abstract available

  300. SAITOH JI, Shirai K, Abe T, Kubo N, et al
    A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:885-891.
    PubMed     Abstract available

  301. VALAN CD, Slagsvold JE, Halvorsen TO, Herje M, et al
    Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
    Anticancer Res. 2018;38:871-876.
    PubMed     Abstract available

  302. GLATZEL-PLUCINSKA N, Piotrowska A, Grzegrzolka J, Olbromski M, et al
    SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
    Anticancer Res. 2018;38:723-736.
    PubMed     Abstract available

  303. KOH YW, Park SY, Hyun SH, Lee SJ, et al
    Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma.
    Anticancer Res. 2018;38:1067-1071.
    PubMed     Abstract available

  304. HIRAI F, Kinoshita I, Matsubara T, Haratake N, et al
    Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?
    Anticancer Res. 2018;38:1041-1045.
    PubMed     Abstract available

  305. ROBELLA M, Vaira M, Borsano A, Mossetti C, et al
    Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
    Anticancer Res. 2018;38:929-932.
    PubMed     Abstract available

  306. KOBAYASHI K, Seike M, Zou F, Noro R, et al
    Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
    Anticancer Res. 2018;38:753-762.
    PubMed     Abstract available

  307. AKIMOTO J, Nakayama M, Takagi S, Okano T, et al
    Improved In Vivo Subcutaneous Tumor Generation by Cancer Cell Sheet Transplantation.
    Anticancer Res. 2018;38:671-676.
    PubMed     Abstract available

  308. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Abstract available

    January 2018
  309. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:559-563.
    PubMed     Abstract available

  310. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:553-557.
    PubMed     Abstract available

  311. SLUGA R, VAN DEN Borne BEEM, Roepman P, Peters BJM, et al
    Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Anticancer Res. 2018;38:393-400.
    PubMed     Abstract available

  312. JUNG CY, Kim SY, Lee C
    Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2018;38:279-286.
    PubMed     Abstract available

  313. SHEN TC, Chang WS, Tsai CW, Chao CY, et al
    The Contribution of Matrix Metalloproteinase-1 Promoter Genotypes in Taiwan Lung Cancer Risk.
    Anticancer Res. 2018;38:253-257.
    PubMed     Abstract available

  314. FANG T, Huang H, Li X, Liao J, et al
    Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:179-186.
    PubMed     Abstract available

  315. DAMASKOS C, Tomos I, Garmpis N, Karakatsani A, et al
    Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
    Anticancer Res. 2018;38:37-43.
    PubMed     Abstract available

  316. PRECIVAL C, Landy M, Poole C, Mullaney L, et al
    The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:7-14.
    PubMed     Abstract available

  317. HIGUCHI T, Yamamoto N, Hayashi K, Takeuchi A, et al
    The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma.
    Anticancer Res. 2018;38:577-582.
    PubMed     Abstract available

    December 2017
  318. TAKADA K, Toyokawa G, Tagawa T, Kohashi K, et al
    Association Between PD-L1 Expression and Metabolic Activity on (18)F-FDG PET/CT in Patients with Small-sized Lung Cancer.
    Anticancer Res. 2017;37:7073-7082.
    PubMed     Abstract available

  319. SHOJI F, Matsubara T, Kozuma Y, Haratake N, et al
    Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6997-7003.
    PubMed     Abstract available

  320. KULDA V, Hrda K, Houdek Z, Dobra JK, et al
    Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6953-6958.
    PubMed     Abstract available

  321. ERBER R, Stohr R, Herlein S, Giedl C, et al
    Comparison of PD-L1 mRNA Expression Measured with the CheckPoint Typer(R) Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:6771-6778.
    PubMed     Abstract available

  322. MATSUBARA T, Toyokawa G, Yamada Y, Nabeshima K, et al
    A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.
    Anticancer Res. 2017;37:6937-6941.
    PubMed     Abstract available

    November 2017
  323. OYA Y, Yoshida T, Kuroda H, Shimizu J, et al
    Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Anticancer Res. 2017;37:6477-6480.
    PubMed     Abstract available

  324. WILLS B, Cardona AF, Rojas L, Ruiz-Patino A, et al
    Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
    Anticancer Res. 2017;37:6429-6436.
    PubMed     Abstract available

  325. TUNGSUKRUTHAI S, Sritularak B, Chanvorachote P
    Cycloartobiloxanthone Inhibits Migration and Invasion of Lung Cancer Cells.
    Anticancer Res. 2017;37:6311-6319.
    PubMed     Abstract available

  326. PINKHIEN T, Petpiroon N, Sritularak B, Chanvorachote P, et al
    Batatasin III Inhibits Migration of Human Lung Cancer Cells by Suppressing Epithelial to Mesenchymal Transition and FAK-AKT Signals.
    Anticancer Res. 2017;37:6281-6289.
    PubMed     Abstract available

  327. MAIUTHED A, Pinkhien T, Chamni S, Suwanborirux K, et al
    Apoptosis-inducing Effect of Hydroquinone 5-O-Cinnamoyl Ester Analog of Renieramycin M on Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:6259-6267.
    PubMed     Abstract available

  328. ICHIHARA H, Kuwabara K, Matsumoto Y
    Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo.
    Anticancer Res. 2017;37:6133-6139.
    PubMed     Abstract available

  329. MORIN C, Fortin S
    Docosahexaenoic Acid Monoglyceride Increases Carboplatin Activity in Lung Cancer Models by Targeting EGFR.
    Anticancer Res. 2017;37:6015-6023.
    PubMed     Abstract available

  330. FIALA O, Hosek P, Pesek M, Finek J, et al
    Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2017;37:6469-6476.
    PubMed     Abstract available

  331. MULLER L, Radtke A, Decker J, Koch M, et al
    The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
    Anticancer Res. 2017;37:6341-6345.
    PubMed     Abstract available

  332. SANOMACHI T, Suzuki S, Kuramoto K, Takeda H, et al
    Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
    Anticancer Res. 2017;37:6177-6188.
    PubMed     Abstract available

    October 2017
  333. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Abstract available

  334. TANIGUCHI Y, Tamiya A, Isa SI, Nakahama K, et al
    Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
    Anticancer Res. 2017;37:5857-5862.
    PubMed     Abstract available

  335. MATSUMOTO Y, Ohara S, Furukawa R, Usui K, et al
    The Prognosis of Small Cell Lung Cancer in Patients with Pulmonary Fibrosis.
    Anticancer Res. 2017;37:5791-5795.
    PubMed     Abstract available

  336. TAKEUCHI A, Oguri T, Sone K, Ito K, et al
    Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Anticancer Res. 2017;37:5771-5776.
    PubMed     Abstract available

  337. SHIBA S, Saitoh JI, Irie D, Shirai K, et al
    Potential Pitfalls of a Fiducial Marker-matching Technique in Carbon-ion Radiotherapy for Lung Cancer.
    Anticancer Res. 2017;37:5673-5680.
    PubMed     Abstract available

  338. SUDO K, Sato K, Sakamoto S, Hasegawa Y, et al
    Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Anticancer Res. 2017;37:5565-5571.
    PubMed     Abstract available

  339. NAKAHAMA K, Isa SI, Tamiya A, Taniguchi Y, et al
    The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.
    Anticancer Res. 2017;37:5885-5891.
    PubMed     Abstract available

  340. HARATAKE N, Toyokawa G, Tagawa T, Kozuma Y, et al
    Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Anticancer Res. 2017;37:5713-5717.
    PubMed     Abstract available

  341. YASUKAWA M, Kawaguchi T, Kawai N, Tojo T, et al
    Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases.
    Anticancer Res. 2017;37:5573-5576.
    PubMed     Abstract available

    September 2017
  342. CELIK E, Semrau R, Baues C, Trommer-Nestler M, et al
    Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5285-5291.
    PubMed     Abstract available

  343. TAMIYA A, Tamiya M, Nakahama K, Taniguchi Y, et al
    Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:5199-5205.
    PubMed     Abstract available

  344. SHINTANI T, Matsuo Y, Iizuka Y, Mitsuyoshi T, et al
    Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy.
    Anticancer Res. 2017;37:5161-5167.
    PubMed     Abstract available

  345. SONE K, Oguri T, Ito K, Kitamura Y, et al
    Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:5125-5131.
    PubMed     Abstract available

  346. ONISHI H, Nakamura K, Nagai S, Yanai K, et al
    Hedgehog Inhibition Upregulates TRK Expression to Antagonize Tumor Suppression in Small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:4987-4992.
    PubMed     Abstract available

  347. HAMAGUCHI R, Okamoto T, Sato M, Hasegawa M, et al
    Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
    Anticancer Res. 2017;37:5141-5145.
    PubMed     Abstract available

  348. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Abstract available

  349. AMPIL F, Ellika S, Nanda A, Vora M, et al
    Long-term Survival After Stereotactic Radiosurgery of Brain Metastases: A Case Series with 10-year Follow-up.
    Anticancer Res. 2017;37:5113-5115.
    PubMed     Abstract available

  350. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Abstract available

  351. TAKENAKA T, Katayama M, Sugiyama A, Hagiwara M, et al
    Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density.
    Anticancer Res. 2017;37:4779-4788.
    PubMed     Abstract available

    August 2017
  352. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Abstract available

  353. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Abstract available

  354. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Abstract available

  355. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Abstract available

  356. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Abstract available

  357. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Abstract available

  358. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Abstract available

  359. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Abstract available

  360. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Abstract available

  361. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Abstract available

  362. ARIYASU R, Horiike A, Yoshizawa T, Dotsu Y, et al
    Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
    Anticancer Res. 2017;37:4229-4232.
    PubMed     Abstract available

    July 2017
  363. YOTSUMOTO F, Fukagawa S, Miyata K, Nam SO, et al
    HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M.
    Anticancer Res. 2017;37:3825-3831.
    PubMed     Abstract available

  364. NAKAO M, Muramatsu H, Kagawa Y, Suzuki Y, et al
    Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
    Anticancer Res. 2017;37:3781-3786.
    PubMed     Abstract available

  365. BANNA GL, Parra HJS, Castaing M, Dieci MV, et al
    Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:3723-3728.
    PubMed     Abstract available

  366. SHEN TC, Hsia TC, Chao CY, Chen WC, et al
    The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer.
    Anticancer Res. 2017;37:3563-3567.
    PubMed     Abstract available

    The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2017;37:3543-3546.
    PubMed     Abstract available

  368. OTSUKA T, Nojiri T, Minami S, Hosoda H, et al
    Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.
    Anticancer Res. 2017;37:3505-3512.
    PubMed     Abstract available

  369. KOBAYASHI H, Hamasaki M, Morishita T, Inoue T, et al
    Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management.
    Anticancer Res. 2017;37:3969-3974.
    PubMed     Abstract available

  370. MARIAMPILLAI AI, Cruz JPD, Suh J, Sivapiragasam A, et al
    Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries.
    Anticancer Res. 2017;37:3649-3656.
    PubMed     Abstract available

    June 2017
  371. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Outcomes of Non-small Cell Lung Cancer in Patients with a History of Pancreaticobiliary Cancer.
    Anticancer Res. 2017;37:3307-3309.
    PubMed     Abstract available

  372. NAKAMICHI S, Seike M, Miyanaga A, Chiba M, et al
    RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients.
    Anticancer Res. 2017;37:3295-3299.
    PubMed     Abstract available

  373. MUTO S, Takagi H, Owada Y, Inoue T, et al
    Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2017;37:3169-3174.
    PubMed     Abstract available

  374. WANG W, Zhong W, Chen C, Meng Q, et al
    Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Anticancer Res. 2017;37:3151-3155.
    PubMed     Abstract available

  375. SINAGRA E, Raimondo D, Gallo E, Stella M, et al
    JC Virus and Lung Adenocarcinoma: Fact or Myth?
    Anticancer Res. 2017;37:3311-3314.
    PubMed     Abstract available

  376. KADERBHAI C, Richard C, Fumet JD, Aarnink A, et al
    Antibiotic Use Does Not Appear to Influence Response to Nivolumab.
    Anticancer Res. 2017;37:3195-3200.
    PubMed     Abstract available

  377. MENCOBONI M, Filiberti RA, Taveggia P, Del Corso L, et al
    Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.
    Anticancer Res. 2017;37:3189-3194.
    PubMed     Abstract available

  378. RIZZARDI C, Athanasakis E, Cammisuli F, Monego SD, et al
    Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy.
    Anticancer Res. 2017;37:3073-3083.
    PubMed     Abstract available

    May 2017
  379. YOSHIDA H, Kim YH, Ozasa H, Nagai H, et al
    EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
    Anticancer Res. 2017;37:2721-2725.
    PubMed     Abstract available

  380. SHOJI F, Toyokawa G, Harada N, Itoh S, et al
    Surgical Treatment and Outcome of Patients with De Novo Lung Cancer After Liver Transplantation.
    Anticancer Res. 2017;37:2619-2623.
    PubMed     Abstract available

  381. JANSSEN S, VAN Oorschot B, Kasmann L, Schild SE, et al
    Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer.
    Anticancer Res. 2017;37:2537-2540.
    PubMed     Abstract available

  382. LIU D, Nakashima N, Nakano J, Tarumi S, et al
    Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Anticancer Res. 2017;37:2501-2507.
    PubMed     Abstract available

  383. DE MARINIS F, Bidoli P, Luciani A, Amoroso D, et al
    EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2457-2464.
    PubMed     Abstract available

  384. CHUANG CL, Wang CH, Hsu CH, Hsiao CL, et al
    Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer.
    Anticancer Res. 2017;37:2417-2423.
    PubMed     Abstract available

  385. LEE AY, Kim S, Lee S, Jiang HL, et al
    Knockdown of Importin 7 Inhibits Lung Tumorigenesis in K-rasLA1 Lung Cancer Mice.
    Anticancer Res. 2017;37:2381-2386.
    PubMed     Abstract available

  386. MASAGO K, Fujita S, Hata A, Okuda C, et al
    PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:2269-2274.
    PubMed     Abstract available

  387. HAO C, Cui Y, Hu MU, Zhi X, et al
    OPN-a Splicing Variant Expression in Non-small Cell Lung Cancer and its Effects on the Bone Metastatic Abilities of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:2245-2254.
    PubMed     Abstract available

  388. TOKUNAGA S, Nagano T, Kobayashi K, Katsurada M, et al
    Amphiregulin as a Novel Resistance Factor for Amrubicin in Lung Cancer Cells.
    Anticancer Res. 2017;37:2225-2231.
    PubMed     Abstract available

  389. AKAMINE T, Toyokawa G, Matsubara T, Kozuma Y, et al
    Significance of the Preoperative CONUT Score in Predicting Postoperative Disease-free and Overall Survival in Patients with Lung Adenocarcinoma with Obstructive Lung Disease.
    Anticancer Res. 2017;37:2735-2742.
    PubMed     Abstract available

  390. JINGU K, Matsuo Y, Onishi H, Yamamoto T, et al
    Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer.
    Anticancer Res. 2017;37:2709-2713.
    PubMed     Abstract available

  391. MIYATA T, Oyama T, Yoshimatsu T, Higa H, et al
    The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma.
    Anticancer Res. 2017;37:2541-2547.
    PubMed     Abstract available

  392. DORE-SAVARD L, Chen Z, Winnard PT Jr, Krishnamachary B, et al
    Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme.
    Anticancer Res. 2017;37:2195-2200.
    PubMed     Abstract available

    April 2017
  393. TSOUKALAS N, Aravantinou-Fatorou E, Tolia M, Giaginis C, et al
    Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1773-1778.
    PubMed     Abstract available

  394. OKAMOTO T, Kohno M, Ito K, Takada K, et al
    Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
    Anticancer Res. 2017;37:1729-1735.
    PubMed     Abstract available

  395. KAITO D, Iihara H, Funaguchi N, Endo J, et al
    Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.
    Anticancer Res. 2017;37:1965-1970.
    PubMed     Abstract available

  396. ABE S, Yamashita SI, Miyahara SO, Wakahara J, et al
    Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma.
    Anticancer Res. 2017;37:1923-1929.
    PubMed     Abstract available

    March 2017
  397. KASMANN L, Bolm L, Janssen S, Rades D, et al
    Prognostic Factors and Treatment of Early-stage Small-cell Lung Cancer.
    Anticancer Res. 2017;37:1535-1537.
    PubMed     Abstract available

  398. YOH K, Goto Y, Naito Y, Kishi K, et al
    Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.
    Anticancer Res. 2017;37:1507-1513.
    PubMed     Abstract available

  399. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    Elevated Metabolic Activity on 18F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:1393-1401.
    PubMed     Abstract available

  400. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Abstract available

  401. TAGAWA T, Ito K, Fukuzawa K, Okamoto T, et al
    Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer.
    Anticancer Res. 2017;37:1413-1416.
    PubMed     Abstract available

  402. BATTOLLA E, Canessa PA, Ferro P, Franceschini MC, et al
    Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Anticancer Res. 2017;37:1387-1391.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.